Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifaximin dosing in Iranian patients with diarrhea-predominant irritable bowel syndrome
IRCT20141201020178N11Phase 3Completed
- Sponsor
- Iran University of Medical Sciences
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of rifaximin in Irritable bowel syndrome with diarrhea (IBS-D), sponsored by Iran University of Medical Sciences. Primary endpoints: Symptom improvement and Quality of life. Started Jan 2022; status: completed.
02
Drugs
rifaximin
03
Conditions
Irritable bowel syndrome with diarrhea (IBS-D)
Beyond the preview
Go deeper on IRCT20141201020178N11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20141201020178N11.